Overview

A Long Term Safety Study of Apricitabine in HIV-infected Patients

Status:
Withdrawn
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study will examine the long term safety of apricitabine in HIV-1 infected patients from studies AVX-301 or AVX-302. Eligible patients are those who have either (a)completed studies AVX-301 or AVX-302; or (b)met the criteria for virological failure/lack of response, and consequently wish to withdraw early from studies AVX-301 or AVX-302.
Phase:
Phase 3
Details
Lead Sponsor:
Avexa